Enveric Biosciences (STU:SLZ0) Short Interest


STU:SLZ0 Enveric Biosciences Inc STU:SLZ0
26 GF Score
Price €55.89
! 1 Warning Sign
View Full Analysis

What is Enveric Biosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:SLZ0 vs ACXP, CELZ, APM: Short Interest Comparison

For the Biotechnology subindustry, Enveric Biosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enveric Biosciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Short Interest falls into.


STU:SLZ0
26GF Score
Enveric Biosciences Inc STU:SLZ0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enveric Biosciences Business Description

Other Exchanges ENVB:USA
Address 245 First Street, 18th Floor, Riverview II, Cambridge, MA, USA, 02142
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
26GF Score

Get the complete analysis for STU:SLZ0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.89
Price